• Marrow transplantation established as a therapeutic paradigm, linking allogeneic grafting with conditioning and graft survival, laying groundwork for clinical protocols and marrow-based therapies [1], [4], [11].

• GVHD becomes the central clinical/pathological constraint, driving diagnostic histopathology, risk assessment, and management trials across donor types and irradiation strategies [10], [13], [16], [19].

• In vitro biology and lineage control of marrow cells underpin transplantation, with studies on culture conditions, proliferation, and lymphopoietic characteristics shaping cell therapy approaches [5], [7], [8], [18].

• Conditioning and radiobiology of marrow transplantation drive engraftment success and GVHD risk, integrating irradiation regimens, marrow radiosensitivity measurements, and ablation strategies into clinical protocols [3], [11], [15], [16].